20 June 2013
Keywords: isis/lilly, ly2181308, advances, clinic, isis, pharmaceuticals, says
Article | 22 November 2004
Isis Pharmaceuticals says that LY2181308, the first antisense drug to emerge from its drug discovery collaboration with Eli Lilly, has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 November 2004
19 June 2013
© 2013 thepharmaletter.com